PhaseBio Pharmaceuticals Overview
Valuation check: PHAS's P/E ratio is -15.58, below the Healthcare sector average of 66.31.
Get informed when a big investor buys or sells
+ Follow-15.58
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
PhaseBio Pharmaceuticals (PHAS) currently reports a P/E ratio of -15.58. That is below the Healthcare sector average of 66.31. Use the charts on this page to explore PhaseBio Pharmaceuticals's P/E ratio history and peer comparisons.
PhaseBio Pharmaceuticals's P/E ratio of -15.58 is lower than the Healthcare sector average of 66.31. That is roughly 123.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates PhaseBio Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -15.58, PHAS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -15.58, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 66.31. From there, open related valuation or income-statement pages for PhaseBio Pharmaceuticals, and consider following PHAS for alerts when major investors trade the stock.
PhaseBio Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -15.58 versus a sector average near 66.31. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHAS with unrelated industries.
